GeNeuro: Half-Yearly Report on the Liquidity Contract with Gilbert Dupont

GENEVA--()--Regulatory News:

Pursuant to the liquidity contract entrusted by GENEURO SA (Paris:GNRO) to Gilbert Dupont, as of June 30, 2017, the following assets appeared on the liquidity account:

  • Number of shares: 33,678
  • Cash balance of the liquidity account: € 284,643.00

As a reminder, as of December 31, 2016, the following resources were booked to the liquidity account:

  • Number of shares: 27,778
  • Cash balance of the liquidity account: € 360,165.12

About GeNeuro

GeNeuro‘s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases such as multiple sclerosis by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.

GeNeuro is based in Geneva, Switzerland and has R&D facilities in France at sites in Archamps, Haute-Savoie and Lyon. It has 31 employees and rights to 16 patent families protecting its technology.

For more information, visit: www.geneuro.com

Market: Euronext Paris
ISIN code / Mnemo: CH0308403085 / GNRO
Web site: www.geneuro.com

Contacts

GeNeuro
Miguel Payró, +41 22 552 48 00
CFO
investors@geneuro.com
or
NewCap (France)
Julien Perez (investors), +33 1 44 71 98 52
Nicolas Merigeau (media), +33 1 44 71 94 98
geneuro@newcap.eu
or
Halsin Partners
Mike Sinclair (media), +44 20 7318 2955
msinclair@halsin.com
or
LifeSci Advisors
Chris Maggos (investors)
+1 646 597 6970
+41 79 367 6254
chris@lifesciadvisors.com

Contacts

GeNeuro
Miguel Payró, +41 22 552 48 00
CFO
investors@geneuro.com
or
NewCap (France)
Julien Perez (investors), +33 1 44 71 98 52
Nicolas Merigeau (media), +33 1 44 71 94 98
geneuro@newcap.eu
or
Halsin Partners
Mike Sinclair (media), +44 20 7318 2955
msinclair@halsin.com
or
LifeSci Advisors
Chris Maggos (investors)
+1 646 597 6970
+41 79 367 6254
chris@lifesciadvisors.com